What we measure
The 2021 AMR Benchmark evaluates how 17 pharmaceutical companies are responding to the global threat of AMR. It has examined company actions relating to medicines and vaccines for bacterial and fungal infections. Find out more about the research scopes.
How we measure
The AMR Benchmark evaluates pharmaceutical companies in areas where they have the biggest potential and responsibility to limit antimicrobial resistance, such as R&D and managing manufacturing waste. Find out more about the analytical framework.
The research process
The Foundation’s Benchmark research team measures company behaviour using a rigorous process of data-collection, verification, scoring and analysis. Find out more about what these phases involve.
How we work with experts
Every two years, the Benchmark methodology is refined based on a targeted review of how stakeholders view pharma’s role in limiting antimicrobial resistance. Find out more about this review and the experts involved.
Antimicrobials have revolutionised medical care. However, most will eventually become obsolete as pathogens develop resistance. Read about the situation and how the AMRB Benchmark stimulates pharmaceutical companies to ensure effective antimicrobials remain available.